Sanofi Genzyme – Humanitarian Aid Program to Treat Rare Diseases

Shannon Resetich, Global Franchise Head, Rare Diseases at Sanofi Genzyme discusses the company’s Humanitarian Aid Program started 30 years ago. The program is largely focused on patients with lysosomal storage disorder (LSDs) diseases who need enzyme replacement therapies. She talks about how this humanitarian program helps to ensure patients with LSDs have access to treatment no matter where they are located or what they can afford. She also discusses how the program works effectively, the partnerships they have forged and the support that the program provides to elevate the standards for rare disease care in the communities around the world. She shares Sanofi Genzyme’s vision moving forward and why this type of program is so essential and should be part of a pharmaceutical company’s mission. 

Shannon Resetich is head of rare diseases and rare blood disorders, North America, with Sanofi Genzyme. She is responsible for driving the growth of these franchises and enabling the company to reach those patients who may benefit from Sanofi Genzyme’s therapies. She has more than twenty years of experience leading cross-functional teams at Fortune 500 companies in the pharmaceutical, healthcare, and consumer packaged goods sectors. She joined Sanofi Genzyme in March of 2018 from Activcore, a start-up concierge physical and performance therapy organization where she served as board director, EVP and chief commercial officer. Prior to joining Activcore, she was global franchise head, hematology at Shire. Prior to Shire’s acquisition of Baxalta, Resetich held positions of increasing responsibility for more than ten years at Baxter/Baxalta. Prior to joining Baxter, she spent multiple years in R&D and brand development with Kraft Foods. For the past four years, Resetich has served on the board of directors of the Healthcare Businesswomen’s Association (HBA) and she is currently the chair. She is a former member of the board of directors for the Illinois Biotechnology Innovation Organization (iBIO). Resetich earned a MBA from the Kellogg School of Management at Northwestern University, and a BS in biological engineering from Purdue University.